title: Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE study.
abstract: Highly active antiretroviral therapy (HAART) is associated with fat redistribution and metabolic disorders. The present study was undertaken to evaluate the association between peroxisome proliferator activated receptor (PPAR)α and PPARγ polymorphisms, two genes involved in lipid metabolism and adipocyte differentiation, and elements of the metabolic syndrome, lipodystrophy, or carbohydrate metabolism abnormalities in patients receiving HAART. The frequency distribution of rare alleles for PPARα (L162V) and PPARγ (P12A and H449H) was compared using the chi square test in 363 HIV-1-infected patients classified according to the presence or absence of the metabolic syndrome after 48 months of follow-up on their first PI-containing regimen. The P12A rare g allele was present in 12% patients with normal glucose metabolism, 11% patients with impaired glucose tolerance or impaired fasting glucose, and 35% patients with diabetes (p=0.014). The rare g allele for L162V was present in 14% of patients free of hypertriglyceridemia and in 7% patients with hypertriglyceridemia (p=0.04). The rare g allele for L162V was found in 15% of patients free of any sign of lipodystrophy and 8% with at least one sign of lipodystrophy (p=0.04) and the rare t allele for H449H was found in 14% of patients free of any sign of lipodystrophy and 23% of patients with at least one sign of lipodystrophy (p=0.05). There was no convincing association between any polymorphism of PPARα and PPARγ and each individual component of the metabolic syndrome, except for the relationship of the P12A polymorphism with diabetes. Confirmatory studies on a larger number of individuals are needed.
authors: Université de Nantes, France.
authors: Hassan
authors: H
authors: Nazih
authors: François
authors: F
authors: Raffi
authors: Audrey
authors: A
authors: Taïeb
authors: Jacques
authors: J
authors: Reynes
authors: Patrick
authors: P
authors: Choutet
authors: Jill-Patrick
authors: JP
authors: Cassuto
authors: Tristan
authors: T
authors: Ferry
authors: Geneviève
authors: G
authors: Chêne
authors: Catherine
authors: C
authors: Leport
authors: Jean-Marie
authors: JM
authors: Bard
mesh_terms: D023241:Antiretroviral Therapy, Highly Active; D016009:Chi-Square Distribution; D005260:Female; D006679:HIV Seropositivity / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D039682:HIV-Associated Lipodystrophy Syndrome / Q000235:genetics* / Q000276:immunology; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000235:genetics* / Q000276:immunology; D047493:PPAR alpha / Q000235:genetics*; D047495:PPAR gamma / Q000235:genetics*; D010865:Pilot Projects; D011110:Polymorphism, Genetic; D011446:Prospective Studies
chemical_list: D047493:PPAR alpha; D047495:PPAR gamma